Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605849 · ClinicalTrials.gov registry record · Phase 3
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 662
- Enrollment target
NCT03605849 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 662 participants.
The verdict
NCT03605849, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 662 participants
- Enrollment target
Study Summary
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
Interventions
- DRUG Centanafadine SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605849
The ClinicalTrials.gov registry entry for NCT03605849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Centanafadine SR is the first listed.
NCT03605849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605849 about?
NCT03605849 is a clinical study titled "A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder". This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
What is the current status of trial NCT03605849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 662 participants. The study started on 2019-02-14. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT03605849?
The interventions under investigation include: Centanafadine SR (DRUG).
Who is sponsoring clinical trial NCT03605849?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.